Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD

Bone Marrow Transplant. 2016 Apr;51(4):607-9. doi: 10.1038/bmt.2015.304. Epub 2015 Dec 7.

Authors

Z DeFilipp¹, M Purcell¹, W A C Harris¹, D J Chandra², C Gleason¹, J Wrammert³, S Sarantopoulos⁴, E K Waller¹

Affiliations

¹ Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
² Medical College of Georgia, Georgia Reagents Univeristy, Augusta, GA, USA.
³ Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA.
⁴ Division of Cell Therapy and Hematologic Malignancies, Department of Medicine, Duke Cancer Institute, Duke University, Durham, NC, USA.

PMID: 26642338
DOI: 10.1038/bmt.2015.304

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Allografts
B-Lymphocytes*
Breast Neoplasms* / blood
Breast Neoplasms* / therapy
Female
Graft vs Host Disease* / blood
Graft vs Host Disease* / drug therapy
Humans
Leukemia, Myeloid, Acute* / blood
Leukemia, Myeloid, Acute* / therapy
Monitoring, Physiologic*
Peripheral Blood Stem Cell Transplantation*
Rituximab / administration & dosage*

Substances

Rituximab

Grants and funding

R01 HL129061/HL/NHLBI NIH HHS/United States